Cellect Biotechnology Ltd (NASDAQ:APOP), a pharmaceuticals, biotechnology and life sciences company based in Israel, saw a significant share price rise of over 20% in the past couple of months on the NasdaqCM. As a small cap stock, hardly covered by any analysts, there is generally more of an opportunity for mispricing as there is less activity to push the stock closer to fair value. Is there still an opportunity here to buy? Today I will analyse the most recent data on APOPs outlook and valuation to see if the opportunity still exists. Check out our latest analysis for Cellect Biotechnology

Are you a shareholder? If you believe APOP should trade below its current price, selling high and buying it back up again when its price falls towards its real value can be profitable. Given the uncertainty from negative growth in the future, this could be the right time to de-risk your portfolio. But before you make this decision, take a look at whether its fundamentals have changed.

Are you a potential investor? If youve been keeping an eye on APOP for a while, now may not be the best time to enter into the stock. Price climbed passed its industry peers, in addition to a risky future outlook. However, there are also other important factors which we havent considered today, such as the financial strength of the company. Should the price fall in the future, will you be well-informed enough to buy?

Price is just the tip of the iceberg. Dig deeper into what truly matters the fundamentals before you make a decision on Cellect Biotechnology. You can find everything you need to know about APOP in the latest infographic research report. If you are no longer interested in Cellect Biotechnology, you can use our free platform to see my list of over 50 other stocks with a high growth potential.

Originally posted here:
Is There Now An Opportunity In Cellect Biotechnology Ltd (APOP)? - Simply Wall St